ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PYXS vs KROS // EV/EBITDA & P/E VALUATION

Pyxis Oncology Inc. (NASDAQ) VS. Keros Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PYXS 1 — KROS 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PYXS VS. KROS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PYXS KROS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 82.80% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 85.00% -120.00 KROS /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% 27.70% -87.70 KROS /operating-margins <GO>
Net Profit Margin -60.00% 35.70% -95.70 KROS /net-margins <GO>
Revenue Growth (YoY) -14.20% 180.00% -194.20 KROS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 4.31 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 8/9 -5.00 KROS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 34.8 40.6 -5.76 KROS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $226.0M $225.2M $776.2K PYXS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PYXS REV KROS REV PYXS GROSS % KROS GROSS % PYXS FCF KROS FCF
FY 2025 $13.9M $244.1M 82.8% — -$63.5M $106.0M
FY 2024 $16.1M $3.5M 97.1% — -$57.9M -$162.8M
FY 2023 $0 $151.0K — — -$70.7M -$124.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PYXS // BETA —
KROS // BETA —